LITTLETON, Colo., Jan. 24, 2013 /PRNewswire/ -- Novus Biologicals LLC, a leading provider of antibodies and reagents to the life science research community, has hired David Eansor to lead a new corporate-development effort.
Eansor, a 13-year veteran in the life science market who was most recently the president of Thermo Fisher Scientific's bioscience division, joined Novus in January as senior vice-president of corporate development. In this new role, Eansor is tasked with accelerating Novus' already impressive growth through a combination of organic investments, licensing and acquisitions of complementary products and capabilities.
"I'm thrilled to join Novus, and for the opportunity to create new growth platforms for this innovative company," Eansor said. "I have watched Novus grow from a niche player to a leader in its space, and I've always been impressed with its commitment to scientific research and outstanding customer service."
"We are so pleased to have an executive of David's caliber join our team, and look forward to many stellar contributions as he expands this critical corporate-development function for us," added Karen Padgett , Novus' founder and chief executive.
Before becoming president of the bioscience division of Thermo Fisher , a publicly traded company, Eansor served as president of the life science research division, acquiring three businesses during his tenure.
Prior to that, he was president of Cambrex Bioproducts, another life science research business focused on cell biology. Eansor also spent 19 years with R.P Scherer Corp., a contract pharmaceutical drug-delivery manufacturer which was acquired by Cardinal Health. He holds a degree in chemistry from the University of Western Ontario as well as a bachelor of commerce and an MBA from the University of Windsor, also in Ontario, Canada.
Novus Biologicals is a leading digital marketing-driven, life science company that supplies antibodies and reagents to the $6 billion global proteomics market. Novus is known for its breadth of quality antibodies and reagents that are well recognized by its global customer base. Based in Littleton, CO, the company was founded in 1996 to license, produce and market antibodies to support niche and emerging areas of research. Now Novus is a global enterprise with a catalog of 180,000 products sold in 60 countries, mainly through its Web site. Novus is backed by Mainsail Partners, a San Francisco growth-equity firm, and has additional offices in Ontario, Canada and Cambridge, UK.
Karen Padgett , President and CEO
Novus Biologicals, LLC
|SOURCE Novus Biologicals LLC|
Copyright©2012 PR Newswire.
All rights reserved